@entity984 Exon 2 Mutations as Prognostic Indicators in Advanced XXXX in Clinical Practice: A Mono-Institutional Study.

@entity1 @entity984 @entity470 @entity409 @entity14 @entity1349
BACKGROUND: @entity984 ( @entity984 ) mutations are widely accepted negative predictive factors for anti- @entity470 therapies in metastatic @entity14 (mCRC), while their prognostic significance is still under discussion. OBJECTIVE: This mono-institutional retrospective study aims to investigate the real-life impact of exon 2 codon 12 and 13 mutations in mCRC. METHODS: All mCRC @entity1 treated at our institution between 2008 and 2014 carrying @entity984 exon 2 mutations were included. The primary endpoint was to determine any significant difference in @entity1349 ( @entity1349 ) between codon 12 and 13 mutations. Secondary endpoints included progression-free survival (PFS), @entity1349 in both populations according to antiangiogenic treatment, and @entity409 ( @entity409 ). RESULTS: Of 620 mCRC @entity1 , 218 carried @entity984 exon 2 mutations (35.1  %): 162 (26.1  %) at codon 12 and 56 (9.0  %) at codon 13. Median @entity1349 results were similar: 32.0  months (codon 12) and 31.0  months (codon 13). PFS was also comparable, reaching 10.8  months in both populations. The addition of bevacizumab to chemotherapy conferred a trend toward survival advantage in codon 12 but not codon 13 mutation (p  =  0.058). A high proportion of @entity409 @entity1 underwent hepatic surgery with radical purpose (62.3  %): in these @entity1 , median @entity1349 has not yet been reached, while @entity1349 in @entity409 @entity1 was 30.2  months. CONCLUSIONS: No difference in @entity1349 between @entity984 codon 12/13 mutated disease was found. This analysis showed a very prolonged @entity1349 for @entity984 -mutated @entity1 , even when @entity409 @entity1 were excluded; @entity1349 of our real-life series favorably compares with @entity1349 of all-RAS wild-type @entity1 in recent randomized studies.
